TY - JOUR
T1 - Treatment options for breast cancer and bone metastases
AU - Pecherstorfer, Martin
PY - 2009/3
Y1 - 2009/3
N2 - The most common destination for breast cancer metastases is bone. If bone metastases are detected, treatment algorithms should include the continuation of cytoreductive therapy with the addition of treatment to counter skeletal-related events, including bone pain. The range of current treatment options includes bisphosphonates, surgical intervention to improve structural integrity and palliative focal radiotherapy. This article focuses on the role of bisphosphonate therapy in metastatic breast cancer. Bisphosphonate therapy significantly reduces the impact of skeletal-related events, reduces bone pain and increases patient quality of life. Our current understanding is that bisphosphonates may also disrupt the metastatic process and reduce the development of bone lesions. Ultimately, this may lead to further expansion of bisphosphonate-based therapy in the future.
AB - The most common destination for breast cancer metastases is bone. If bone metastases are detected, treatment algorithms should include the continuation of cytoreductive therapy with the addition of treatment to counter skeletal-related events, including bone pain. The range of current treatment options includes bisphosphonates, surgical intervention to improve structural integrity and palliative focal radiotherapy. This article focuses on the role of bisphosphonate therapy in metastatic breast cancer. Bisphosphonate therapy significantly reduces the impact of skeletal-related events, reduces bone pain and increases patient quality of life. Our current understanding is that bisphosphonates may also disrupt the metastatic process and reduce the development of bone lesions. Ultimately, this may lead to further expansion of bisphosphonate-based therapy in the future.
KW - Bone Density Conservation Agents/therapeutic use
KW - Bone Neoplasms/diagnosis
KW - Bone Resorption/prevention & control
KW - Breast Neoplasms/pathology
KW - Chemotherapy, Adjuvant
KW - Diphosphonates/therapeutic use
KW - Female
KW - Humans
KW - Quality of Life
KW - Radiotherapy, Adjuvant
KW - Randomized Controlled Trials as Topic
UR - http://www.scopus.com/inward/record.url?scp=67650160594&partnerID=8YFLogxK
U2 - 10.2217/17455057.5.2.149
DO - 10.2217/17455057.5.2.149
M3 - Review article
C2 - 19245353
SN - 1745-5057
VL - 5
SP - 149
EP - 163
JO - Women's Health
JF - Women's Health
IS - 2
ER -